National Institute for Innovation in Manufacturing Biopharmaceuticals

What National Institute for Innovation in Manufacturing Biopharmaceuticals does

NIIMBL is a public-private partnership institute founded in 2017 that accelerates innovation in U.S. biopharmaceutical manufacturing. It operates as one of the federally sponsored Manufacturing USA institutes, funded primarily through a cooperative agreement with the National Institute of Standards and Technology (NIST) within the U.S. Department of Commerce. The institute serves a broad ecosystem of over 200 member organizations, which as of June 30, 2023 were distributed approximately 51% industry, 30% academia, 16% nonprofits, and 3% government. Its members include large pharmaceutical enterprises (Merck, GSK, AstraZeneca, Bristol-Myers Squibb), academic research institutions, community colleges, federal agencies (FDA, NIH, NSF, NCI, DOD, HHS, DFC), and global health organizations.

Name

National Institute for Innovation in Manufacturing Biopharmaceuticals

Legal name

National Institute for Innovation in Manufacturing Biopharmaceuticals

Website

https://niimbl.org

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

NIIMBL is a Manufacturing USA public-private partnership that accelerates U.S. biopharmaceutical manufacturing innovation through collaborative programs, member-driven R&D projects, industry standards, and workforce development across 200+ member organizations.

Ownership category

akta.pro rank

Headquarters

HQ city

Newark

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Federal Government Funding: NIIMBL receives primary funding through a cooperative agreement with the National Institute of Standards and Technology (NIST) in the U.S. Department of Commerce. Additional federal support comes from member stakeholder agencies including FDA, NIH, NSF, NCI, DOD, HHS, and DFC.
2. Membership Dues: Tiered membership structure with annual fees ranging from $1,000 (Tier 3 Academic) to $650,000 (Tier 1 Industry) plus leveraged cost share. Industry tiers include Tier 1 ($650,000), Tier 2 ($450,000), Affiliate Silver ($250,000), Affiliate Bronze ($100,000), and Tier 3 ($5,000-$15,000 based on company size). Academic tiers range from $1,000 to $40,000 in kind.
3. Gates Foundation Grants: NIIMBL leads teams selected for external funding awards, such as the $10.5 million Gates Foundation Grand Challenge for low-cost monoclonal antibody manufacturing technologies.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

NIIMBL operates as a public-private partnership institute that accelerates biopharmaceutical manufacturing innovation through member-driven collaborative programs, technology projects, and workforce development. It manages four NIIMBL-led technical programs (Big Data, Process Intensification, Preventive Medical Countermeasures, Viral Vector Manufacturing), a Project Call Program that funds member-led technology and workforce projects, and Industry Solutions such as the BRLs framework, Buffer Stock Blending System, N-mAb case study, and technology roadmaps. Access to programs, IP benefits, and shared platforms is delivered through tiered membership for industry, academic, and non-profit organizations.

Product overview

NIIMBL is a public-private partnership offering a portfolio of collaborative programs, platforms, and resources for biopharmaceutical manufacturing innovation. The core offerings include four NIIMBL-led programs (Big Data, Process Intensification, Preventive Medical Countermeasures, Viral Vector Manufacturing), a Project Call Program for member-driven technology and workforce projects, and Industry Solutions including the BRLs Framework, Buffer Stock Blending System, N-mAb case study, and technology roadmaps. Workforce development is supported through the NIIMBL eXperience program, Faculty Fellows program, and Equipment in Residence collaboration with FDA.

Differentiator

Problem solved

Functional benefit

Brands

• Ammon Pinizzotto Biopharmaceutical Innovation Center: The 200,000 square foot facility on the University of Delaware campus that serves as NIIMBL headquarters, housing administrative offices, shared laboratory space, process facilities, showcase laboratory, and workforce training areas.
• Process Intensification Program
• Big Data Program
• Preventive Medical Countermeasures Program
• Viral Vector Manufacturing and Analytics Program
• NIIMBL BioPhorum Buffer Stock Blending System
• N-mAb
• Biomanufacturing Readiness Levels (BRLs)

Products and services

• Project Call Program

Quantifiable outcome

• Carbon footprint reductions of up to 51% and plastic waste reductions of up to 57% when comparing end-to-end continuous processes to intensified fed-batch production (per Sartorius data)
• +2 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered major, core and minor.

• Sartorius StedimmajorStrategic or Co-development Partner · 23 October 2025Sartorius participates as a key partner in the Gates Foundation-funded project led by NIIMBL for low-cost monoclonal antibody manufacturing technology development.
• Manufacturing USAcoreStrategic or Co-development PartnerNIIMBL is a proud member of Manufacturing USA, a network of federally sponsored manufacturing innovation institutes. This affiliation provides access to cross-institute collaboration, federal support through NIST, and recognition as part of the national manufacturing innovation infrastructure.
• U.S. Food and Drug Administration (FDA)coreStrategic or Co-development PartnerFDA collaborates with NIIMBL on the Equipment in Residence Program (EiRP), whereby new and emerging manufacturing-related and analytical measurement technologies are made temporarily available to FDA staff for research and demonstration purposes. Technologies selected reside in FDA labs for 3-12 months.
• Open Applications Group (OAGi)coreStrategic or Co-development PartnerPartnership to develop open-source biopharmaceutical manufacturing ontologies, released in November 2025, to advance interoperability and analytics across the biopharmaceutical manufacturing ecosystem.
• BioPhorumcoreStrategic or Co-development PartnerCollaboration with BioPhorum to design, build, and test the NIIMBL-BioPhorum Buffer Stock Blending System, a full-scale cGMP system that delivers buffer on-demand at commercial scale with significant cost savings.
• Federal Stakeholder AgenciescoreStrategic or Co-development PartnerFederal stakeholders including Department of Defense, Health & Human Services, National Cancer Institute, National Institutes of Health, National Science Foundation, and U.S. International Development Finance Corporation participate as members supporting NIIMBL's mission.
• Alliance for Regenerative MedicinemajorStrategic or Co-development PartnerCollaboration on Project A-Gene and Project A-Cell, case studies integrating Quality by Design principles into gene therapy and CAR-T therapy CMC programs.
• Fraunhofer UKminorStrategic or Co-development PartnerFraunhofer UK leads the InSPIREmed project under Innovate UK's Sustainable Medicines Manufacturing Innovation Programme to reduce waste and lower utility consumption in pharmaceutical production through advanced process analytical technology.

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Market position

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/niimbl
• Xx.com/NIIMBL
• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments15 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Institute for Innovation in Manufacturing Biopharmaceuticals